B+
Bull case
30%
Probability
Target price
$102.00
+15.0% vs current
ARWR
ArrowheadCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-22
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$84.00
-5.3% vs current
B-
Bear case
25%
Probability
Target price
$62.00
-30.1% vs current
AI sentiment snapshot
Latest data as of 2026-06-18
Recent news sentiment (30D)
+0.4
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+41.3
Score
AI commentary
Primary-source tone is constructive, and the stock's June 17, 2026 anchor of $81.04 is above the roughly $78 level cited by AP on May 7, 2026 after earnings, so the post-print move has held and improved. Still, the packet does not provide robust post-print analyst target-revision evidence, and the thesis remains dependent on launch conversion plus regulatory and clinical checkpoints rather than broad estimate support. The peer frame is now strongest around IONS for APOC3 launch dynamics, MDGL for MASH-linked program optionality, and BMRN for rare-disease commercialization, but this remains a monitoring-style moderately positive setup rather than a high-conviction rerating call.
RankAlpha Sentiment Codex - 2026-06-18
Open full AI memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators
Impact
tentative
Confidence
-
AI events
2026-06-30eventEuropean Commission decision on REDEMPLO is a near-dated ex-U.S. validation pointHigh impact
Arrowhead's May 7, 2026 8-K said the CHMP issued a positive opinion and that the European Commission was expected to issue a REDEMPLO marketing-authorization decision in calendar Q2 2026; approval would extend the first-product commercialization story beyond the U.S. and support later launches in select EU markets, while delay would weaken the near-term expansion narrative [#SEC-8K-2026-05-07].
2026-08-31catalystREDEMPLO launch conversion needs to show paid-claim durabilityMedium impact
Arrowhead's May 7, 2026 earnings release said REDEMPLO prescriptions received and in process exceeded 400, about 180 patients had received at least one shipment, and new written prescriptions were averaging about 30 per week; the next decision point is whether those early launch metrics convert into cleaner reimbursed revenue and better gross-to-net visibility rather than staying a shipment-heavy early-access story [#SEC-8K-2026-05-07].
2026-12-31catalystARO-INHBE follow-through could broaden value beyond triglyceride diseaseHigh impact
Arrowhead's May 27, 2026 company release reported clinically meaningful liver-fat reductions for ARO-INHBE as monotherapy and with low-dose tirzepatide, plus continued improvement in visceral fat and liver fat through Week 24, and said the company is engaging regulators on Phase 2 designs and endpoints for MASH and obesity; formal next-trial design clarity or advancement would matter because it is one of the clearest non-REDEMPLO platform value drivers now visible [#IR-2026-05-27].
Recommendation
N/A
No formal recommendation provided.
As of 2026-06-18 • Updated nightlySource: Internal modelMethodology